Northwestern Medicine at ASH 2024: Shaping the Future of Hematology
Join Northwestern Medicine experts at the 66th ASH Annual Meeting on December 7-10, 2024. They will be presenting a wide array of hematology research and insights.
Related Articles
Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy
This study examines a modified progressive disease classification and its association with postprogression survival in patients treated with atezolizumab across various solid tumors.
FDA Grants Taletrectinib Priority Review for Advanced ROS1+ NSCLC
Taletrectinib demonstrated favorable efficacy and tolerability data in the TRUST-I and TRUST-II trials for the treatment of patients with advanced non–small cell lung cancer.
National Childhood Cancer Registry
NCCR collects data and publishes statistics to better understand the causes, outcomes, effective treatments, and later effects of cancer among children, adolescents, and young adults…
Keto Fuel for CAR-T Therapy: The Role of Dietary Interventions | ASH News Daily | American Society of Hematology
Almost every patient with a cancer diagnosis has asked me, “How should I change my diet?” Yesterday’s Plenary Scientific Session, Ketogenic Diet Enhances CAR-T Cell…
IASLC, LCRF Announce First Recipients of Joint Team Science Award Aimed at Finding a Cure for Oncogene-Driven Lung Cancers – ILCN.org (ILCN/WCLC)
Dr. David Barbie and his team will receive a 4-year, $2.5 million grant to support their research on immune-based approaches to target drug-resistant cancer cells.
Jhaveri Compares Safety and Duration of Adjuvant CDK4/6 Inhibitors in HR+ Breast Cancer
During a Case-Based Roundtable® event, Komal Jhaveri, MD, FACP, discussed dosing and toxicity concerns with the approved CDK4/6 inhibitor regimens used in the adjuvant setting for…
GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation – The Cancer Letter
In an industry that set its sights on reshaping cancer detection, GRAIL Inc. had the appearance of a pioneer. To access this subscriber-only content please…
Aditya Bardia, MD, on Destiny-Breast06: An Additional Analysis
Aditya Bardia, MD, of UCLA David Geffen School of Medicine, Los Angeles, presents the additional analysis of the efficacy and safety of trastuzumab deruxtecan vs…
#ASH2424: Mantle cell lymphoma
Catch up with our live social media coverage of indolent and mantle cell lymphoma, from the American Society of Hematology (ASH) 2024 Meeting and Exposition.
